BioWorld

Nov. 6, 2003

View Archived Issues

Scleroderma Plot Thickens, First On Skin, Ultimately Hits Internally, Sometimes Fatally

Read More

Pursuing Growth Via Acquisition Strategy, Invitrogen Buys Sequitur

Read More

Other News To Note

Read More

Esperion Makes Up Ground On Positive Phase II Results

After losing 26 percent of its stock value on rumors that upcoming news regarding its cardiovascular drug would be negative, Esperion Therapeutics Inc. recovered when positive data were published. (BioWorld Today) Read More

FDA Backs Cloned Livestock, Suggests More Data Prudent

Read More